Jiangsu Alphamab Biopharmaceutical
-
Newtown Square’s ArriVent Partners With Chinese Firm on Cancer Drug
ArriVent Biopharma in Newtown Square has made a deal valued up to $615 million with a Chinese firm on a cancer drug development, writes John…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
